Heart Failure Clinical Trial
Wireless, Intermittent Monitoring of Right Heart Pressures in HF
Summary
The purpose of the trial is to evaluate the wireless monitoring of pulmonary artery pressure using the CardioMEMS HF Pressure Measurement System in adult subjects with NYHA Class III Heart Failure.
Full Description
The trial is designed to demonstrate that the CardioMEMS Sensor can be positioned in the right or left pulmonary artery, and that Sensor pressure measurements correlate to standardized methods of intra-cardiac pressure measurements post-sensor implant and at the 60 day visit. Safety will be monitored by the occurrence of adverse events throughout the trial.
Eligibility Criteria
Inclusion Criteria:
Subject is male or female, at least 18 years of age
Subjects of childbearing age who have a negative serum pregnancy test, and at screening have agreed to use a reliable mechanical or hormonal form of conception during the study.
Subject has a diagnosis of New York Heart Association (NYHA) Class III HF at screening and at baseline.
Subject is able and willing to provide written informed consent or the subject guardian is able and willing to provide informed consent.
Subject has life expectancy of 1-2 years.
Exclusion Criteria:
Subject has unstable medical condition or impairment other than a medical condition associated with HF which would significantly increase the subject's morbidity or mortality risk.
Subject is unable to tolerate a right heart catheterization.
Subject is planned to undergo a heart transplantation or cardiac surgery within 2 months after enrollment.
Subject has permanent indwelling central venous catheter.
Subject has history of myocardial infarction (MI), unstable angina, stroke, transient ischemic attack, or intractable arrhythmias within last 2 months.
Subject has history of congenital heart disease or prosthetic valve on right side.
Subject has unstable hypertension.
Subject has a known coagulability disease state.
Subject has a known hypersensitivity and/or allergy to aspirin and clopidogrel.
Subject has active lung infection or acute pulmonary decompensation.
Subject has elevated white blood cell count and signs of infection are evident.
Subject has chronic renal insufficiency as defined by serum creatinine of greater than or equal to 2 mg/dl or requirement for dialysis.
Subject who is pregnant or lactating or might become pregnant during the duration of the study.
Subject who is participating in another therapeutic interventional trial.
Subject has other medical, psychological, or social circumstances that may affect the ability to comply with the study requirements or increase risk to the subject.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 4 Locations for this study
Atlanta Georgia, 30313, United States
Columbus Ohio, 43085, United States
Oklahoma City Oklahoma, 73120, United States
Nashville Tennessee, 37201, United States
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.